DrugPatentWatch Database Preview
Eyepoint Pharms Company Profile
Email this page to a colleague
» See Plans and PricingWhat is the competitive landscape for EYEPOINT PHARMS, and when can generic versions of EYEPOINT PHARMS drugs launch?
EYEPOINT PHARMS has two approved drugs.
There are eleven US patents protecting EYEPOINT PHARMS drugs.
There are one hundred and eighty-four patent family members on EYEPOINT PHARMS drugs in thirty-one countries and five supplementary protection certificates in four countries.
Summary for Eyepoint Pharms
| International Patents: | 184 |
| US Patents: | 11 |
| Tradenames: | 2 |
| Ingredients: | 2 |
| NDAs: | 2 |
Drugs and US Patents for Eyepoint Pharms
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Eyepoint Pharms | YUTIQ | fluocinolone acetonide | IMPLANT;INTRAVITREAL | 210331-001 | Oct 12, 2018 | RX | Yes | Yes | 8,574,613 | Start Trial | Y | Start Trial | |||
| Eyepoint Pharms | YUTIQ | fluocinolone acetonide | IMPLANT;INTRAVITREAL | 210331-001 | Oct 12, 2018 | RX | Yes | Yes | 8,574,659 | Start Trial | Y | Start Trial | |||
| Eyepoint Pharms | DEXYCU KIT | dexamethasone | SUSPENSION;INTRAOCULAR | 208912-001 | Feb 9, 2018 | RX | Yes | Yes | 10,022,502 | Start Trial | Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Eyepoint Pharms
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Eyepoint Pharms | YUTIQ | fluocinolone acetonide | IMPLANT;INTRAVITREAL | 210331-001 | Oct 12, 2018 | 9,849,085 | Start Trial |
| Eyepoint Pharms | YUTIQ | fluocinolone acetonide | IMPLANT;INTRAVITREAL | 210331-001 | Oct 12, 2018 | 9,192,579 | Start Trial |
| Eyepoint Pharms | YUTIQ | fluocinolone acetonide | IMPLANT;INTRAVITREAL | 210331-001 | Oct 12, 2018 | 6,217,895 | Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for Eyepoint Pharms Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| European Patent Office | 1583747 | Start Trial |
| Taiwan | I290054 | Start Trial |
| Denmark | 1635787 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Eyepoint Pharms Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2233112 | 132014902285293 | Italy | Start Trial | PRODUCT NAME: FLUOCINOLONE ACETONIDE(ILUVIEN); AUTHORISATION NUMBER(S) AND DATE(S): 042616019, 20140530;PL27813/0001, 20120504 |
| 1581193 | SPC/GB12/047 | United Kingdom | Start Trial | PRODUCT NAME: DEXAMETHASONE; REGISTERED: UK EU/1/10/638/001 20100727 |
| 1429780 | 13C0012 | France | Start Trial | PRODUCT NAME: COMBINAISON DE CIPROFLOXACINE ET DE DEXAMETHASONE, EN PARTICULIER DE CHLORHYDRATE DE CIPROFLOXACINE ET DE DEXAMETHASONE; NAT. REGISTRATION NO/DATE: NL 41308 20121214; FIRST REGISTRATION: 48976 20120808 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
